Custom service
Drug-Tolerant ADA Assays
Detect ada in samples with high circulating drug levels
Drug-Tolerant ADA Assays supports programmes that detect ADA in samples with high circulating drug levels. In a typical engagement we plan the acid dissociation and bead-based pretreatment route first, confirm compatibility with drug-tolerant bridging formats, and release drug-tolerant assay with validation data on a 8–12 weeks schedule.
Chemistry is chosen for the molecule, not from a menu. Where the payload tolerates it we keep acid dissociation and bead-based pretreatment as the primary option and hold drug-tolerant bridging formats in reserve, so that scale-up never depends on an unproven step.
High-dose biologics where standard ADA fails
Re-dosing programs after immunogenicity signals
Products with manageable drug interference
Samples requiring containment or licensing we do not hold (BSL-3, radioactive)
Analytical reports follow a fixed template: sample condition on receipt, method description with validation status, raw chromatograms and spectra, results with uncertainty, and an interpretation note. Urgent same-week slots are available for release-critical testing.
Service Highlights
- Acid dissociation and bead-based pretreatment as the default route, with drug-tolerant bridging formats held as a proven fallback
- Drug-interference characterization worked into the design where the application requires it
- Results are reported with detection limits and method validation status, so you know exactly what the number means
- Analytical confirmation of every intermediate before the final release
- Orthogonal methods are used by default — one measurement is an observation, two are data
- Drug-tolerant assay with validation data delivered with a complete conjugation or synthesis certificate
How the work runs
Sample intake & plan
Samples are logged with chain of custody and the test matrix for Drug-Tolerant ADA Assays is confirmed.
Method selection
Analytical methods — acid dissociation and bead-based pretreatment, drug-tolerant bridging formats — are chosen and their validation status documented.
Measurement
Testing is executed with system-suitability checks and orthogonal confirmation where required.
Data review
Chromatograms and spectra are reviewed by a second analyst before any result is issued.
Reporting
Drug-tolerant assay with validation data is issued with detection limits and interpretation notes.
Follow-up support
We discuss anomalies and, where useful, propose the follow-up experiment that resolves them.
Specifications & timeline
- Turnaround
- 8–12 weeks
- Typical scale
- µg – g sample scale
- Chemistry options
- acid dissociation and bead-based pretreatment; drug-tolerant bridging formats; drug-interference characterization
- Deliverable
- Drug-tolerant assay with validation data
- QC package
- Method report, raw data, validated result with detection limits
- Shipping
- Blue ice or ambient by material; chain-of-custody on receipt
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.